News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Trump Claims Iran Requested Delay in Strikes; US Stocks Post Largest Drop Since US-Iran Conflict Began; Apple Opens Siri to External AI (March 27, 2026)2US-Iran Tensions Latest: Diplomatic Deadlock Drives Market Fluctuations as Trump Prolongs Suspension of Attacks on Energy Facilities3Bitcoin gained 655% the last time this supply in profit metric dropped to 50%
Couche-Tard’s Fuel Margin Surge Powers Earnings Beat Despite Revenue Miss—Can This Reset the Growth Narrative?
101 finance·2026/03/19 03:48
Copper Gives Up 2026 Advances Amid Metal Market Turmoil Caused by Iran Conflict
101 finance·2026/03/19 03:48
Crypto's $228M Outflow: Where the Capital Is Heading
101 finance·2026/03/19 03:48
Evernorth's $1B SPAC: Flow Assessment at $2.44
101 finance·2026/03/19 03:48
SanDisk Surges Amid AI Storage Boom—Will It Stay Above $750?
101 finance·2026/03/19 03:48
Ushio’s Direction Overlooks Yen Depreciation and Slump in Semiconductors—Event-Driven Opportunity Arises
101 finance·2026/03/19 03:40
Why Is Bitcoin Declining Even With $1.1 Billion Flowing Into ETFs
101 finance·2026/03/19 03:36
Energy Vaults Earnings Surge, But Profit Remains Elusive
101 finance·2026/03/19 03:36
Elixir CEO’s discounted purchase reflects careful confidence as Omega makes a calculated strategic move
101 finance·2026/03/19 03:33
Horizon’s Cue Takeover Relying on Retail Sentiment and a Weak Skin-in-the-Game Signal from the CEO
101 finance·2026/03/19 03:33
Flash
19:32
Eli Lilly announced that its combination therapy of Taltz and Zepbound achieved the primary endpoint and all key secondary endpoints in a 36-week study period, with data showing that this combination therapy was statistically significantly superior to Taltz monotherapy.This groundbreaking achievement highlights the synergistic effect of combination therapy, providing new clinical evidence for the treatment of related diseases. A comprehensive analysis of the research data will further support the prospects for the application of this therapy.
19:32
Incyte presented the latest positive 54-week data on its investigational drug Povorcitinib for the treatment of hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.These delayed but important breakthrough research results further validate the long-term efficacy and safety of this therapy, bringing new hope to patients.
19:31
MoonLake Immunotherapeutics officially released the 40-week key data from the phase III clinical trial of its innovative drug Sonelokimab for the treatment of moderate to severe hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.The results announced this time further validate the drug’s long-lasting efficacy and favorable safety profile, offering new hope for patients’ treatment.
News